COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

Mizuho Neuro & Ophthalmology Summit 2025

Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET

Jefferies Global Healthcare Conference

Presentation: Thursday, June 5, 2025, at 1:25 p.m. ET

The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

Media Contact:

Cheryl Wheeler

Head of Corporate Communications



        





EN
19/05/2025

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Gu...

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3...

3h / 14m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her P...

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment ​​​– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, entrepreneur, musician, ​author, and advocate, ​are collaborating ​​to share her personal experience living ...

October 29, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Third Quarter 2025 Financial Results on November 6...

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio we...

October 23, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces Poster Presentations at the American Academy of Ch...

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neur...

October 22, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ri...

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing – Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in celebration of its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market. “Since its inception, Collegium has remained dedicated to improving the lives of patients with serious medical conditions. That commitment has fueled both our growth and the im...

October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch